Galenica completes acquisition of Relypsa Freitag, 02. September 2016 - 07:02
Friday, 2 September 2016, ↓ directly to download
Galenica completes acquisition of Relypsa, strengthening Vifor Pharma’s position in cardio-renal therapies
- Combination with Relypsa strengthens Vifor Pharma’s position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
- Vifor Pharma to build on Relypsa’s fully-integrated commercial organisation in key US cardio-renal market by leveraging its extensive and growing specialty portfolio
Galenica Group today announced that it has completed its previously announced acquisition of Relypsa, Inc., (NASDAQ: RLYP). The combination of Galenica’s Vifor Pharma Business unit with Relypsa will create a significant player in cardio-renal care in the USA and further strengthen Vifor Pharma’s growing international leadership in cardiology, nephrology and gastroenterology therapies.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).